Skip to content

Liver Metabolic Functions in Patients With Citrin Deficiency and Healthy Subjects

Assessment of Liver Metabolic Alterations in Vivo in Patients With Citrin Deficiency and Healthy Subjects by Metabolic Labeling With Stable Isotopes

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07055269
Enrollment
20
Registered
2025-07-08
Start date
2025-10-20
Completion date
2026-09-30
Last updated
2026-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Citrin Deficiency

Keywords

Citrin Deficiency, Adolescent and Adult Citrin Deficiency, AACD, SLC25A13, liver metabolic flux, ureagenesis, Citrin

Brief summary

Citrin is an aspartate-glutamate transporter in the liver that facilitates the urea cycle pathway for ammonia detoxification via ureagenesis. It is also thought to be involved in liver energy metabolism as a component of the malate-aspartate shuttle. The clinical presentation in patients supports the hypothesis that liver glycolytic, gluconeogenic and lipogenic functions are compromised in citrin deficiency, but none of the key hepatic pathway fluxes have been measured in patients to date. This is the first study that will examine the liver metabolic fluxes in patients with citrin deficiency. Liver metabolic functions will be examined by metabolic flux assays and biochemical measurements after application of stable isotopes 2H2O and \[U-13C6\]-fructose. Urea cycle metabolites and their enrichment after application of a stable isotope tracer 15NH4Cl will be measured to examine the liver's ability to detoxify ammonia into urea.

Interventions

OTHERliver metabolic flux

All participants will be given heavy water (2H2O, deuterium-labelled) and \[U-13C6\]-fructose orally, each followed by the collection of one blood plasma sample. Additional biochemical and clinical parameters including liver fat content by MRI, liver fibrosis and cirrhosis by ultrasound imaging and plasma biochemical profiles will be analyzed.

OTHERureagenesis capacity

urea and urea cycle metabolites and their enrichment after oral administration of a stable isotope tracer 15NH4Cl will be measured to examine the liver's ability to detoxify ammonia.

Sponsors

Citrin Foundation
CollaboratorUNKNOWN
Marc Hellerstein, University of Berkeley
CollaboratorUNKNOWN
Johannes Haeberle
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Cross-sectional observational study, non-randomised

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

for AACD patients are: * Subjects with citrin deficiency, confirmed by genetic analysis to carry pathogenic variant(s) in the SLC25A13 gene * Age from 18 years to 65 years inclusive * Male or female * Written informed consent has been given * Understands and is willing, able and likely to comply with study procedures and restrictions Inclusion criteria for healthy subjects are: * Age from 18 years to 65 years inclusive, and not more than five years younger or older than the specified paired participant from the AACD group * Same sex as the specified paired participant from the AACD group * Same ethnicity the specified paired participant from the AACD group * Written informed consent has been given * Understands and is willing, able and likely to comply with study procedures and restrictions

Exclusion criteria

for AACD patients are: * acute and chronic disease requiring treatment of any kind, other than his/her AACD * females who are pregnant or lactating or attempting to become pregnant * use of any medication which, in the opinion of the investigator, is likely to interfere with liver function

Design outcomes

Primary

MeasureTime frameDescription
Liver metabolic flux5 daysLiver metabolic flux will be measured by assessing the distribution of the administered isotope tracers \[U-13C6\]-fructose and heavy water.

Secondary

MeasureTime frameDescription
Ureagenesis capacity1 dayPatients will receive an oral dose of 2 mg/kg of the 15NH4Cl tracer diluted in water. Blood will be collected at various time points up to 2 hours after tracer administration to assess the body's ability to remove ammonia.
adverse events5 daysSafety and tolerability of 2H2O, \[U-13C6\]-fructose and 15NH4Cl
liver fat content1 dayMagnetic resonance imaging of the liver for fat content
Liver fibrosis1 dayUltrasound imaging of the liver to assess fibrosis and cirrhosis
Clinical symptoms1 dayClinical presentation and fatigue will be measured through questionnaires

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026